Skip to main content
Top
Published in: Journal of Thrombosis and Thrombolysis 3/2014

01-04-2014

Platelet distribution width and the risk of periprocedural myocardial infarction in patients undergoing percutaneous coronary intervention

Authors: Monica Verdoia, Lucia Barbieri, Alon Schaffer, Ettore Cassetti, Gabriella Di Giovine, Giorgio Bellomo, Paolo Marino, Fabiola Sinigaglia, Giuseppe De Luca

Published in: Journal of Thrombosis and Thrombolysis | Issue 3/2014

Login to get access

Abstract

Periprocedural myocardial infarction (PMI) still occurs in a large amount of percutaneous coronary interventions (PCI), mainly due to increased platelet activation. Platelet size has been suggested as an indicator of enhanced reactivity and platelet distribution width (PDW) could reflect morphologic changes in platelets, therefore affecting their function and potentially increasing the risk of complications after coronary stenting. Aim of the present study was to evaluate the relationship between PDW and PMI. We included 1,300 consecutive patients undergoing PCI. Myonecrosis biomarkers were dosed at intervals from 6 to 48 h after PCI. Periprocedural myonecrosis was defined as troponin I increase by three times the ULN or by 50 % of an elevated baseline value, whereas PMI as CKMB increase by three times the ULN or 50 % of baseline. We grouped patients according to tertiles values of PDW (<12.1; ≥13.9). Higher PDW was associated with age (p = 0.03), diabetes (p < 0.001), previous cerebrovascular accidents (p = 0.04), therapy with statins (p = 0.001) and ARBs (p < 0.001), ASA (p = 0.02), nitrates (p = 0.006), calcium antagonists (p = 0.05) and lower pre-procedural clopidogrel bolus (p = 0.005). PDW related with haemoglobin levels (p < 0.001), while inversely to platelet count (p < 0.001) and glycaemia (p = 0.003). Patients with larger PDW had lower presence of coronary thrombus (p < 0.001), higher rate of coronary calcifications (p = 0.02), higher stenting rate (p = 0.03) and lower rate of distal embolization (p = 0.03). Larger PDW did not increase risk of PMI (p = 0.11; adjusted OR [95 % CI] = 0.94 [0.78–1.1], p = 0.55) or periprocedural myonecrosis (p = 0.73; adjusted OR [95 % CI] = 0.95 [0.82–1.1], p = 0.51). Results were confirmed even in higher-risk subgroups of patients. In patients undergoing coronary stenting, PDW does not increase the risk of periprocedural MI and therefore should not be considered a risk factor for thrombotic periprocedural complications after PCI.
Literature
1.
go back to reference Califf RM, Abdelmeguid AE, Kuntz RE et al (1998) Myonecrosis after revascularization procedures. J Am Coll Cardiol 31:241–251PubMedCrossRef Califf RM, Abdelmeguid AE, Kuntz RE et al (1998) Myonecrosis after revascularization procedures. J Am Coll Cardiol 31:241–251PubMedCrossRef
2.
go back to reference De Luca G, Bellandi F, Huber K, Noc M, Petronio AS, Arntz HR, Maioli M, Gabriel HM, Zorman S, DE Carlo M, Rakowski T, Gyongyosi M, Dudek D (2011) Early glycoprotein IIb–IIIa inhibitors in primary angioplasty-abciximab long-term results (EGYPT-ALT) cooperation: individual patient’s data meta-analysis. J Thromb Haemost 9:2361–2370CrossRef De Luca G, Bellandi F, Huber K, Noc M, Petronio AS, Arntz HR, Maioli M, Gabriel HM, Zorman S, DE Carlo M, Rakowski T, Gyongyosi M, Dudek D (2011) Early glycoprotein IIb–IIIa inhibitors in primary angioplasty-abciximab long-term results (EGYPT-ALT) cooperation: individual patient’s data meta-analysis. J Thromb Haemost 9:2361–2370CrossRef
3.
go back to reference De Luca G, Smit JJ, Ernst N, Suryapranata H, Ottervanger JP, Hoorntje JC, Dambrink JH, Gosslink AT, de Boer MJ, van ‘t Hof AW (2005) Impact of adjunctive tirofiban administration on myocardial perfusion and mortality in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction. Thromb Haemost 93:820–823PubMed De Luca G, Smit JJ, Ernst N, Suryapranata H, Ottervanger JP, Hoorntje JC, Dambrink JH, Gosslink AT, de Boer MJ, van ‘t Hof AW (2005) Impact of adjunctive tirofiban administration on myocardial perfusion and mortality in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction. Thromb Haemost 93:820–823PubMed
4.
go back to reference De Luca G, Cassetti E, Verdoia M, Marino P (2009) Bivalirudin as compared to unfractionated heparin among patients undergoing coronary angioplasty: a meta-analysis of randomised trials. Thromb Haemost 102:428–436PubMed De Luca G, Cassetti E, Verdoia M, Marino P (2009) Bivalirudin as compared to unfractionated heparin among patients undergoing coronary angioplasty: a meta-analysis of randomised trials. Thromb Haemost 102:428–436PubMed
5.
go back to reference De Luca G, Dudek D, Sardella G, Marino P, Chevalier B, Zijlstra F (2008) Adjunctive manual thrombectomy improves myocardial perfusion and mortality in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized trials. Eur Heart J 29:3002–3010PubMedCrossRef De Luca G, Dudek D, Sardella G, Marino P, Chevalier B, Zijlstra F (2008) Adjunctive manual thrombectomy improves myocardial perfusion and mortality in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized trials. Eur Heart J 29:3002–3010PubMedCrossRef
6.
go back to reference Navarese EP, Kubica J, Castriota F, Gibson CM, Buffon A, Bolognese L, Margheri M, Andreotti F, Di Mario C, De Servi S (2011) Safety and efficacy of biodegradable versus durable polymer drug-eluting stents: evidence from a meta-analysis of randomised trials. EuroIntervention 7:985–994PubMedCrossRef Navarese EP, Kubica J, Castriota F, Gibson CM, Buffon A, Bolognese L, Margheri M, Andreotti F, Di Mario C, De Servi S (2011) Safety and efficacy of biodegradable versus durable polymer drug-eluting stents: evidence from a meta-analysis of randomised trials. EuroIntervention 7:985–994PubMedCrossRef
7.
go back to reference De Luca G, Suryapranata H, Chiariello M (2006) Prevention of distal embolization in patients undergoing mechanical revascularization for acute myocardial infarction. A review of current status. Thromb Haemost 96:700–710PubMed De Luca G, Suryapranata H, Chiariello M (2006) Prevention of distal embolization in patients undergoing mechanical revascularization for acute myocardial infarction. A review of current status. Thromb Haemost 96:700–710PubMed
8.
go back to reference Herrmann J (2005) Peri-procedural myocardial injury: 2005 update. EurHeart J 26:2493–2519 Herrmann J (2005) Peri-procedural myocardial injury: 2005 update. EurHeart J 26:2493–2519
9.
go back to reference Michaels AD, Gibson CM, Barron HV (2000) Microvascular dysfunction in acute myocardial infarction: focus on the roles of platelet and inflammatory mediators in the no-reflow phenomenon. Am J Cardiol 85:50b–60bPubMedCrossRef Michaels AD, Gibson CM, Barron HV (2000) Microvascular dysfunction in acute myocardial infarction: focus on the roles of platelet and inflammatory mediators in the no-reflow phenomenon. Am J Cardiol 85:50b–60bPubMedCrossRef
10.
go back to reference Tsiara S, Elisaf M, Jagroop IA, Mikhailidis DP (2003) Platelets as predictors of vascular risk: Is there a practical index of platelet activity? Clin Appl Thromb Hemost 9:177–190PubMedCrossRef Tsiara S, Elisaf M, Jagroop IA, Mikhailidis DP (2003) Platelets as predictors of vascular risk: Is there a practical index of platelet activity? Clin Appl Thromb Hemost 9:177–190PubMedCrossRef
11.
go back to reference Martin JF, Trowbridge EA, Salmon G, Plumb J (1983) The biological significance of platelet volume: its relationship to bleeding time, thromboxane B2 production and megakaryocyte nuclear DNA concentration. Thromb Res 32:443–460PubMedCrossRef Martin JF, Trowbridge EA, Salmon G, Plumb J (1983) The biological significance of platelet volume: its relationship to bleeding time, thromboxane B2 production and megakaryocyte nuclear DNA concentration. Thromb Res 32:443–460PubMedCrossRef
12.
go back to reference Vagdatli E, Gounari E, Lazaridou E, Katsibourlia E, Tsikopoulou F, Labrianou I (2010) Platelet distribution width: a simple, practical and specific marker of activation of coagulation. Hippokratia. 14(1):28–32PubMedCentralPubMed Vagdatli E, Gounari E, Lazaridou E, Katsibourlia E, Tsikopoulou F, Labrianou I (2010) Platelet distribution width: a simple, practical and specific marker of activation of coagulation. Hippokratia. 14(1):28–32PubMedCentralPubMed
13.
go back to reference Boos CJ, Beevers GD, Lip GY (2007) Assessment of platelet activation indices using the ADVIATM 120 amongst ‘high-risk’ patients with hypertension. Ann Med 39(1):72–78PubMedCrossRef Boos CJ, Beevers GD, Lip GY (2007) Assessment of platelet activation indices using the ADVIATM 120 amongst ‘high-risk’ patients with hypertension. Ann Med 39(1):72–78PubMedCrossRef
14.
go back to reference Ihara A, Kawamoto T, Matsumoto K, Shouno S, Morimoto T, Noma Y (2006) Relationship between hemostatic factors and the platelet index in patients with ischemic heart disease. Pathophysiol Haemost Thromb 35:388–391PubMedCrossRef Ihara A, Kawamoto T, Matsumoto K, Shouno S, Morimoto T, Noma Y (2006) Relationship between hemostatic factors and the platelet index in patients with ischemic heart disease. Pathophysiol Haemost Thromb 35:388–391PubMedCrossRef
15.
go back to reference Amin MA, Amin AP, Kulkarni HR (2004) Platelet distribution width (PDW) is increased in vaso-occlusive crisis in sickle cell disease. Ann Hematol 83:331–335PubMedCrossRef Amin MA, Amin AP, Kulkarni HR (2004) Platelet distribution width (PDW) is increased in vaso-occlusive crisis in sickle cell disease. Ann Hematol 83:331–335PubMedCrossRef
16.
go back to reference Tozkoparan E, Deniz O, Ucar E, Bilgic H, Ekiz K (2007) Changes in platelet count and indices in pulmonary tuberculosis. Clin Chem Lab Med 45:1009–1013PubMedCrossRef Tozkoparan E, Deniz O, Ucar E, Bilgic H, Ekiz K (2007) Changes in platelet count and indices in pulmonary tuberculosis. Clin Chem Lab Med 45:1009–1013PubMedCrossRef
17.
go back to reference De Luca G, Secco GG, Santagostino M, Venegoni L, Iorio S, Cassetti E, Verdoia M, Coppo L, Di Mario C, Bellomo G, Marino P (2012) Uric acid does not affect the prevalence and extent of coronary artery disease. Results from a prospective study. Nutr Metab Cardiovasc Dis 22:426–433PubMedCrossRef De Luca G, Secco GG, Santagostino M, Venegoni L, Iorio S, Cassetti E, Verdoia M, Coppo L, Di Mario C, Bellomo G, Marino P (2012) Uric acid does not affect the prevalence and extent of coronary artery disease. Results from a prospective study. Nutr Metab Cardiovasc Dis 22:426–433PubMedCrossRef
18.
go back to reference De Luca G, Santagostino M, Secco GG, Cassetti E, Giuliani L, Franchi E, Coppo L, Iorio S, Venegoni L, Rondano E, Dell’Era G, Rizzo C, Pergolini P, Monaco F, Bellomo G, Marino P (2009) Mean platelet volume and the extent of coronary artery disease: results from a large prospective study. Atherosclerosis 206:292–297PubMedCrossRef De Luca G, Santagostino M, Secco GG, Cassetti E, Giuliani L, Franchi E, Coppo L, Iorio S, Venegoni L, Rondano E, Dell’Era G, Rizzo C, Pergolini P, Monaco F, Bellomo G, Marino P (2009) Mean platelet volume and the extent of coronary artery disease: results from a large prospective study. Atherosclerosis 206:292–297PubMedCrossRef
19.
go back to reference Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD (2012) Joint ESC/ACCF/AHA/WHF Task Force for Universal Definition of Myocardial Infarction. Third universal definition of myocardial infarction. J Am Coll Cardiol 60:1581–1598PubMedCrossRef Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD (2012) Joint ESC/ACCF/AHA/WHF Task Force for Universal Definition of Myocardial Infarction. Third universal definition of myocardial infarction. J Am Coll Cardiol 60:1581–1598PubMedCrossRef
20.
go back to reference Siller-Matula J, Schrör K, Wojta J, Huber K (2007) Thienopyridines in cardiovascular disease: focus on clopidogrel resistance. Thromb Haemost 97:385–393PubMed Siller-Matula J, Schrör K, Wojta J, Huber K (2007) Thienopyridines in cardiovascular disease: focus on clopidogrel resistance. Thromb Haemost 97:385–393PubMed
21.
go back to reference Kabbani SS, Aggarwal A, Terrien EF, DiBattiste PM, Sobel BE, Schneider DJ (2002) Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions. Am J Cardiol 89:647–650PubMedCrossRef Kabbani SS, Aggarwal A, Terrien EF, DiBattiste PM, Sobel BE, Schneider DJ (2002) Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions. Am J Cardiol 89:647–650PubMedCrossRef
22.
go back to reference Cuisset T, Frere C, Quilici J, Morange PE, Nait-Saidi L, Mielot C, Bali L, Lambert M, Alessi MC, Bonnet JL (2007) High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes. Thromb Haemost 97:282–287PubMed Cuisset T, Frere C, Quilici J, Morange PE, Nait-Saidi L, Mielot C, Bali L, Lambert M, Alessi MC, Bonnet JL (2007) High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes. Thromb Haemost 97:282–287PubMed
23.
go back to reference Kamath S, Blann AD, Lip GY (2001) Platelet activation: assessment and quantification. Eur Heart J 22:1561–1571PubMedCrossRef Kamath S, Blann AD, Lip GY (2001) Platelet activation: assessment and quantification. Eur Heart J 22:1561–1571PubMedCrossRef
24.
go back to reference Park Y, Schoene N, Harris W (2002) Mean platelet volume as an indicator of platelet activation: methodological issues. Platelets 13(5–6):301–306PubMedCrossRef Park Y, Schoene N, Harris W (2002) Mean platelet volume as an indicator of platelet activation: methodological issues. Platelets 13(5–6):301–306PubMedCrossRef
25.
go back to reference Khandekar MM, Khurana AS, Deshmukh SD, Kakrani AL, Katdare AD, Inamdar AK (2006) Platelet volume indices in patients with coronary artery disease and acute myocardial infarction: an Indian scena. J Clin Pathol 59(2):146–149PubMedCentralPubMedCrossRef Khandekar MM, Khurana AS, Deshmukh SD, Kakrani AL, Katdare AD, Inamdar AK (2006) Platelet volume indices in patients with coronary artery disease and acute myocardial infarction: an Indian scena. J Clin Pathol 59(2):146–149PubMedCentralPubMedCrossRef
26.
go back to reference Ege MR, Guray U, Guray Y, Acıkgoz S (2012) Demirkan B. Association with graft occlusion. Herz, Platelet distribution width and saphenous vein disease in patients after CABG Ege MR, Guray U, Guray Y, Acıkgoz S (2012) Demirkan B. Association with graft occlusion. Herz, Platelet distribution width and saphenous vein disease in patients after CABG
27.
go back to reference Gasparyan AY, Ayvazyan L, Mikhailidis DP, Kitas GD (2011) Mean platelet volume: A link between thrombosis and inflammation? Curr Pharm Des 17(1):47–58PubMedCrossRef Gasparyan AY, Ayvazyan L, Mikhailidis DP, Kitas GD (2011) Mean platelet volume: A link between thrombosis and inflammation? Curr Pharm Des 17(1):47–58PubMedCrossRef
28.
go back to reference Schoos MM, Kelbæk H, Kofoed KF, Køber L, Kløvgaard L, Helqvist S, Engstrøm T, Saunamäki K, Jørgensen E, Holmvang L, Clemmensen P (2011) Usefulness of preprocedure high-sensitivity C-reactive protein to predict death, recurrent myocardial infarction, and stent thrombosis according to stent type in patients with ST-segment elevation myocardial infarction randomized to bare metal or drug-eluting stenting during primary percutaneous coronary intervention. Am J Cardiol 107(11):1597–1603PubMedCrossRef Schoos MM, Kelbæk H, Kofoed KF, Køber L, Kløvgaard L, Helqvist S, Engstrøm T, Saunamäki K, Jørgensen E, Holmvang L, Clemmensen P (2011) Usefulness of preprocedure high-sensitivity C-reactive protein to predict death, recurrent myocardial infarction, and stent thrombosis according to stent type in patients with ST-segment elevation myocardial infarction randomized to bare metal or drug-eluting stenting during primary percutaneous coronary intervention. Am J Cardiol 107(11):1597–1603PubMedCrossRef
29.
go back to reference De Luca G, Venegoni L, Iorio S, Secco GG, Cassetti E, Verdoia M, Schaffer A, Coppo L, Bellomo G, Marino P (2010) Novara Atherosclerosis Study Group. Platelet distribution width and the extent of coronary artery disease: results from a large prospective study. Platelets 21(7):508–514PubMedCrossRef De Luca G, Venegoni L, Iorio S, Secco GG, Cassetti E, Verdoia M, Schaffer A, Coppo L, Bellomo G, Marino P (2010) Novara Atherosclerosis Study Group. Platelet distribution width and the extent of coronary artery disease: results from a large prospective study. Platelets 21(7):508–514PubMedCrossRef
30.
go back to reference Lippi G, Meschi T, Borghi L (2012) Mean platelet volume increases with aging in a large population study. Thromb Res 129(4):e159–e160PubMedCrossRef Lippi G, Meschi T, Borghi L (2012) Mean platelet volume increases with aging in a large population study. Thromb Res 129(4):e159–e160PubMedCrossRef
31.
go back to reference Jindal S, Gupta S, Gupta R, Kakkar A, Singh HV, Gupta K, Singh S (2011) Platelet indices in diabetes mellitus: indicators of diabetic microvascular complications. Hematology. 16(2):86–89PubMedCrossRef Jindal S, Gupta S, Gupta R, Kakkar A, Singh HV, Gupta K, Singh S (2011) Platelet indices in diabetes mellitus: indicators of diabetic microvascular complications. Hematology. 16(2):86–89PubMedCrossRef
32.
go back to reference Jagroop IA, Mikhailidis DP (2000) Angiotensin II can induce and potentiate shape change in human platelets: effect of losartan. J Hum Hypertens 14(9):581–585PubMedCrossRef Jagroop IA, Mikhailidis DP (2000) Angiotensin II can induce and potentiate shape change in human platelets: effect of losartan. J Hum Hypertens 14(9):581–585PubMedCrossRef
33.
go back to reference Sato Y, Fujii S, Imagawa S, Ohmura K, Ohmura Y, Andoh Y, Dong J, Ishimori N, Furumoto T, Tsutsui H (2007) Platelet aggregability in patients with hypertension treated with angiotensin II type 1 receptor blockers. J Atheroscler Thromb 14(1):31–35PubMedCrossRef Sato Y, Fujii S, Imagawa S, Ohmura K, Ohmura Y, Andoh Y, Dong J, Ishimori N, Furumoto T, Tsutsui H (2007) Platelet aggregability in patients with hypertension treated with angiotensin II type 1 receptor blockers. J Atheroscler Thromb 14(1):31–35PubMedCrossRef
34.
go back to reference Coban E, Afacan B (2008) The effect of rosuvastatin treatment on the mean platelet volume in patients with uncontrolled primary dyslipidemia with hypolipidemic diet treatment. Platelets 19:111–114PubMedCrossRef Coban E, Afacan B (2008) The effect of rosuvastatin treatment on the mean platelet volume in patients with uncontrolled primary dyslipidemia with hypolipidemic diet treatment. Platelets 19:111–114PubMedCrossRef
35.
go back to reference Hansen JB, Berge LN, Svensson B, Lyngmo V, Nordøy A (1993) Effects of cod liver oil on lipids and platelets in males and females. Eur J Clin Nutr 47:123–131PubMed Hansen JB, Berge LN, Svensson B, Lyngmo V, Nordøy A (1993) Effects of cod liver oil on lipids and platelets in males and females. Eur J Clin Nutr 47:123–131PubMed
36.
go back to reference Smith NM, Pathansali R, Bath PM (2002) Altered megakaryocyte-platelet-haemostatic axis in patients with acute stroke. Platelets 13:113–120PubMedCrossRef Smith NM, Pathansali R, Bath PM (2002) Altered megakaryocyte-platelet-haemostatic axis in patients with acute stroke. Platelets 13:113–120PubMedCrossRef
37.
go back to reference Senaran H, Ileri M, Altinbas A, Kosar A, Yetkin E, Ozturk M et al (2001) Thrombopoietin and mean platelet volume in coronary artery disease. Clin Cardiol 24:405–408PubMedCrossRef Senaran H, Ileri M, Altinbas A, Kosar A, Yetkin E, Ozturk M et al (2001) Thrombopoietin and mean platelet volume in coronary artery disease. Clin Cardiol 24:405–408PubMedCrossRef
38.
go back to reference Korovesis S, Fredericks S, Holt D, Toutouzas P, Kaski JC, Webb-Peploe MM, Katritsis D (2000) Release of platelet activation markers during coronary angioplasty. Coron Artery Dis 11:391–398PubMedCrossRef Korovesis S, Fredericks S, Holt D, Toutouzas P, Kaski JC, Webb-Peploe MM, Katritsis D (2000) Release of platelet activation markers during coronary angioplasty. Coron Artery Dis 11:391–398PubMedCrossRef
39.
go back to reference Beyan C, Kaptan K, Ifran A (2006) Platelet count, mean platelet volume, platelet distribution width, and plateletcrit do not correlate with optical platelet aggregation responses in healthy volunteers. J Thromb Thrombolysis 22(3):161–164PubMedCrossRef Beyan C, Kaptan K, Ifran A (2006) Platelet count, mean platelet volume, platelet distribution width, and plateletcrit do not correlate with optical platelet aggregation responses in healthy volunteers. J Thromb Thrombolysis 22(3):161–164PubMedCrossRef
Metadata
Title
Platelet distribution width and the risk of periprocedural myocardial infarction in patients undergoing percutaneous coronary intervention
Authors
Monica Verdoia
Lucia Barbieri
Alon Schaffer
Ettore Cassetti
Gabriella Di Giovine
Giorgio Bellomo
Paolo Marino
Fabiola Sinigaglia
Giuseppe De Luca
Publication date
01-04-2014
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 3/2014
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-013-0954-4

Other articles of this Issue 3/2014

Journal of Thrombosis and Thrombolysis 3/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.